Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.

<h4>Background</h4>Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy.<h4>Methods</h4>Patients with primary triple negati...

Full description

Bibliographic Details
Main Authors: Serena Di Cosimo, Nicla La Verde, Anna Moretti, Marina Elena Cazzaniga, Daniele Generali, Giulia Valeria Bianchi, Luigi Mariani, Valter Torri, Flavio Crippa, Biagio Paolini, Gianfranco Scaperrotta, Maria Carmen De Santis, Massimo Di Nicola, Giovanni Apolone, Alessandro Gulino, Claudio Tripodo, Mario Paolo Colombo, Secondo Folli, Filippo de Braud
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0220644

Internet

https://doi.org/10.1371/journal.pone.0220644

Similar Items